Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has entered into an agreement with InNeuroCo for exclusive US and European distribution rights for intermediate catheters that are designed to enable minimally invasive treatment of haemorrhagic stroke. The announcement was made at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting.
The agreement includes the InNeuroCo intermediate catheter (IC) and the InNeuroCo super distal access (SDA) device. According to a company release, the InNeuroCo IC, which has received regulatory approval in the US and Europe, has shown optimised tracking during insertion. The InNeuroCo SDA is currently pending US Food and Drug Administration (FDA) 510 (k) clearance. The catheters will be offered alongside the full line of Codman Neuro microcatheters and guiding catheters, which support the delivery of neurovascular products including the Codman Enterprise 2 vascular reconstruction device.
“Intermediate catheters are increasingly used by neurovascular specialists to facilitate the delivery of other devices, including stents and thrombectomy devices for the treatment of stroke,” says P Laxmin Laxminarain, worldwide president of Codman Neuro.
The Codman Enterprise vascular reconstruction device and the Codman Enterprise 2 vascular reconstruction device are approved by the FDA under a Humanitarian Device Exemption (HDE) in the USA, where it is authorised for use with embolic coils for the treatment of wide-neck, intracranial, saccular or fusiform aneurysms arising from a parent vessel with a diameter of ≥2.5mm and ≤4mm.
